Supporting this notion, we found that the anti‐tumor response mediated by intratumoral injections of anti‐NKG2A/Qa‐1b plus activated NK cells was greatly improved by the administration of intraperitoneal anti‐PD‐1 mAb (Fig 5A–C). This evidence concerns the gene KLRC1 and neoplasm.